Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

133.65EUR
11:35am EST
Change (% chg)

€0.30 (+0.22%)
Prev Close
€133.35
Open
€133.00
Day's High
€134.50
Day's Low
€132.55
Volume
1,675,636
Avg. Vol
2,408,205
52-wk High
€134.50
52-wk Low
€91.31

BAYGn.DE

Chart for BAYGn.DE

About

Bayer AG is a German holding company active in the field of health care, nutrition and high-tech materials. It has three subgroups: HealthCare, involved in the research, development and production of health products for people and animals, CropScience, engaged in the crop protection and non-agricultural pest control, and... (more)

Overall

Beta: 0.87
Market Cap(Mil.): €105,270.50
Shares Outstanding(Mil.): 826.95
Dividend: 2.10
Yield (%): 1.65

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 28.79 38.98 40.20
EPS (TTM): 4.42 -- --
ROI: 8.83 17.01 16.34
ROE: 18.18 17.52 17.27
Search Stocks

Bayer crown prince vows independence for diversified drugmaker

LEVERKUSEN, Germany - Werner Baumann, seen as heir apparent to Bayer Chief Executive Marijn Dekkers, says he will fight for the independence of Germany's largest drugmaker after the spin-off of its plastics unit.

27 Feb 2015

Deals of the day- Mergers and acquisitions

Feb 26 - The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Thursday:

26 Feb 2015

BRIEF-Bayer says receives EU approval for Eylea for new indication

* Bayer news release: not intended for u.s. And uk media - bayer receives eu approval for eylea for the treatment of retinal vein occlusion

26 Feb 2015

Bayer says would consider attractive bid for MaterialScience

LEVERKUSEN, Germany, Feb 26 - Bayer's chief executive said the drugmaker would have to consider any attractive takeover offer for the MaterialScience unit, which Bayer plans to list on the stock exchange, but he signalled that jobs security would be taken into account.

26 Feb 2015

Bayer counting on new stroke drug as it targets double-digit earnings growth

LEVERKUSEN, Germany - Germany's largest drugmaker Bayer said it expects underlying core earnings to increase by more than 10 percent this year, banking on a boost from new drugs such as stroke prevention pill Xarelto.

26 Feb 2015

UPDATE 2-Bayer counting on new stroke drug as it targets double-digit earnings growth

* Q4 adj EBITDA, net income short of poll average (Adds research costs, expected one-offs, spin-off plans, shares)

26 Feb 2015

CORRECTED-Bayer eyes earnings growth in 2015 on new drugs

LEVERKUSEN, Germany, Feb 26 - Germany's largest drugmaker Bayer said it expects growth in underlying core earnings in the low to mid-teens percentage range this year, as it gets a boost from new drugs such as stroke prevention pill Xarelto.

26 Feb 2015

Bayer names new chairman for MaterialScience business

FRANKFURT, Feb 25 - Germany's Bayer named Richard Pott as supervisory board chairman of its plastics unit MaterialScience, which it plans to float on the stock market as a separate company.

25 Feb 2015

Bayer lifts dividend to 2.25 euros/share

FRANKFURT, Feb 25 - Germany's largest drugmaker Bayer said it would propose an annual dividend of 2.25 euros ($3) per share to investors, a tad more than the 2.23 euros expected on average by analysts.

25 Feb 2015

Bayer diabetes business sale not imminent: sources

FRANKFURT - German drugmaker Bayer is in talks to sell its diabetes devices division but a sale is not imminent, two sources with knowledge of the matter told Reuters.

20 Feb 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Directors Deals Ltd.
$12.00
Provider: Finlabo SIM Spa
$10.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks